Nexalis Therapeutics has issued share rights to directors in lieu of fees, with vesting contingent on successful Phase 2 clinical trial completion, aiming to conserve cash for ongoing drug development.
- Share rights issued to directors instead of cash fees
- Vesting depends on success of Phase 2 clinical trials
- Board applied a higher deemed issue price than formula
- Capital preserved for clinical programs and corporate costs
- Directors risk forfeiting fees if Phase 2 milestones fail
Share Rights Replace Director Fees with Clinical Trial Contingency
Nexalis Therapeutics (ASX:NX1) has adopted a novel approach to director remuneration by issuing share rights in place of cash fees for the first half of 2026. The rights, granted to current director Sean Williams and former director Tony Fitzgerald, will only vest upon successful completion of the company’s Phase 2 clinical trials. This structure aligns director compensation directly with key clinical milestones, underscoring the company’s commitment to advancing its drug candidates while conserving cash.
Pricing Mechanism Reflects Trial Success Probability and Board Discretion
The number of share rights issued was calculated using a pricing mechanism approved at the May 2026 AGM, which factors in the 30-day volume weighted average price (VWAP) of Nexalis shares and a 35% likelihood of Phase 2 trial success. This probability exceeds typical industry benchmarks, reflecting a cautiously optimistic outlook. Despite the formula indicating a deemed issue price of $0.0086 per share right, the board exercised discretion to use a higher price of $0.0163, consistent with the company’s last capital raise in November 2025. This decision reduces the total number of rights issued, potentially limiting dilution.
Director Fees Deferred Pending Clinical Progress
Sean Williams received 2.64 million share rights in lieu of $42,924 in fees, while Tony Fitzgerald, who resigned in June, was issued 1.5 million rights prorated to his tenure. The share rights vest only if any of the company’s Phase 2 clinical trials for IRX-211 (Breakthrough Cancer Pain), IRX-616a (Panic Disorder), or SRX-25 (Treatment-Resistant Depression) succeed. Failure to meet these conditions means the rights lapse and the directors effectively forgo remuneration for that period.
Capital Management Strategy Prioritises Clinical Development
This remuneration approach fits neatly into Nexalis’s broader capital management strategy, which seeks to preserve available funds for its clinical programs and corporate overheads. With the company recently completing its IRX-616a Phase 1 trial and progressing its Phase 2 studies, the move to pay directors with performance-linked equity underscores a focus on efficient capital deployment amid ongoing clinical and funding challenges.
Bottom Line?
Nexalis’s director fee structure ties compensation directly to clinical success, spotlighting the high stakes and capital discipline shaping its drug development journey.
Questions in the middle?
- Will the Phase 2 clinical trials meet the 35% success threshold to trigger share rights vesting?
- How might the board’s choice of a higher deemed issue price affect future shareholder dilution?
- Could this remuneration model influence investor perceptions of Nexalis’s capital management and clinical risk?